samedan logo
 
 
 
spacer
home > ebr
PUBLICATIONS

European Biopharmaceutical Review

 

European Biopharmaceutical Review (EBR) is a journal designed to fill a unique position in scientific publishing. Published quarterly, it provides a dedicated platform of communication and information for the European biopharmaceutical market across Europe, North America, and the rest of the world.

With editorial consisting of in-depth articles, case studies, meetings, and report reviews written by specialists with hands-on experience in the biopharma industry; traditional multi-national pharma companies; investment houses; and industry-associated governmental, economic, and societal bodies. Each quarterly edition examines topical areas of importance across the board of biopharmaceutical research and development, with regular feature sections on BioBusiness Development, Research and Innovation, BioDiscovery, BioManufacturing plus special focuses on geographic or therapeutic territories.

For further information please contact:

Advertising

Helga Schweissguth


Editorial

George Grant
 

 

 

Connect with us on Twitter: follow @EBRmagazine
   

   


Click here to view the digital version of EBR

 

 


 


Click here to view the digital version of EBR BIO-Europe Supplement

 

 

 

ebr
 
 
Featured in this issue
Infectious Diseases
Infectious Diseases

The Future of Vaccines for Infectious Diseases

How we can make better use of the often-overlooked power of cytotoxic T cells using arenaviruses in the development of vaccines for infectious diseases.

Klaus Orlinger, Henning Lauterbach, Daniel Pinschewer, and Igor Matushansky at HOOKIPA Pharma
Rare Diseases
Rare Diseases

Pooling Efforts to Drive Gene Therapies for Rare Diseases

A three-pronged approach that will drive gene therapies to market in a more efficient and financially viable way, and then ultimately into the hands of patients. This requires improved collaboration across the biopharma industry.

Christian Schneider at Biopharma Excellence
  AI in Drug Discovery
AI in Drug Discovery

The Rise of Machine Learning and What it Means For Biological and Chemical Data

Despite advances, there is still one bottleneck holding back more significant developments in drug discovery. What are the problems, and how should they be addressed?

Nil Adell-Mill at Arctoris

spacer


Published quarterly in
January, April,
July, and October


 

 
News and Press Releases

ACG introduces Smart Connected Product to enable remote machine monitoring in real-time

Mumbai 12th January, 2022 - New solution improves machine efficiency, prevents breakdowns, lowers costs and reduces risks whilst providing anytime, anywhere remote monitoring. ACG, the world’s leading integrated solutions provider for pharmaceutical companies, has introduced the Smart Connected Product - a new, innovative, IIoT solution, that connects production machines at any facility and visualises relevant information on a single platform. This data can be viewed over the web on any device with a secure connection and is accessible only to authorised users.
More info >>

 
White Papers

Key to Outsourcing Method Development and Validation A Pragmatic Approach

RSSL

In an industry that is seeing an increasing level of work being outsourced, the Contract Research Organisation (CRO) of choice needs to have proven experience in both the pragmatism and flexibility of the method developer’s mind set and a regulatory background in validation.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement